President Donald Trump has claimed Kenvue’s pain reliever is a potential cause of autism, despite clear evidence.
Key Facts
Kimberly-Clark will pay $21.01 a share for Kenvue in a cash-and-stock deal valued at $48.
Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal
